Published in Rheumatol Int on November 15, 2011
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol (2012) 1.06
Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus. Rheumatol Int (2015) 0.91
[Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy]. Ophthalmologe (2016) 0.90
Aqueous Humor Levels of Different Interleukins 1-β, 2, 6 and 10, Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in Uveitis Treated with Adalimumab. J Ophthalmic Vis Res (2015) 0.86
Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. Am J Ophthalmol (2015) 0.83
Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm (2013) 0.83
Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol (2015) 0.82
Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J (2016) 0.81
Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int (2015) 0.78
Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatr Rheumatol Online J (2016) 0.78
The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. Paediatr Drugs (2015) 0.77
Uveitis in children. Curr Opin Rheumatol (2016) 0.75
[Not Available]. Ophthalmologe (2014) 0.75
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2016) 0.75
Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis. Curr Treatm Opt Rheumatol (2017) 0.75
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology (1985) 3.83
Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum (1977) 3.51
Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med (1992) 2.62
Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology (2001) 2.61
Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum (2001) 2.27
Double-blind clinical trial of topical steroids in anterior uveitis. Br J Ophthalmol (1979) 2.24
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Early predictors of severe course of uveitis in oligoarticular juvenile idiopathic arthritis. J Rheumatol (2002) 1.90
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol (2007) 1.82
Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol (2005) 1.81
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum (2004) 1.71
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol (2007) 1.66
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology (2010) 1.54
Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol (2003) 1.51
Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) (2007) 1.49
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2006) 1.47
Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) (2006) 1.47
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology (2006) 1.46
Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology (1987) 1.45
Optic neuritis associated with etanercept therapy in two patients with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) (2005) 1.42
Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics (2006) 1.41
Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr (1998) 1.39
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Juvenile arthritis and uveitis. Surv Ophthalmol (1990) 1.35
Visual loss in uveitis of childhood. Br J Ophthalmol (2003) 1.33
Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology (1997) 1.30
Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology (2001) 1.28
Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology (2006) 1.27
Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology (2006) 1.27
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology (2001) 1.21
Ocular manifestations of juvenile rheumatoid arthritis. Am J Ophthalmol (1975) 1.20
Adalimumab therapy for childhood uveitis. J Pediatr (2006) 1.20
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) (2008) 1.20
Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis (2006) 1.19
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) (2000) 1.18
The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol (1974) 1.13
Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol (1977) 1.12
Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology (2003) 1.07
Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus (1999) 1.05
Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol (1991) 1.04
Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol (1998) 1.04
Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Experiment Ophthalmol (2005) 1.03
Laser flare photometry and complications of chronic uveitis in children. Am J Ophthalmol (2003) 1.02
Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol (2006) 1.02
[Vision-threatening complications in childhood uveitis]. Ophthalmologe (2005) 1.02
Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol (2003) 1.02
Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology (2008) 1.01
Double-masked controlled clinical trial of 5% tolmetin versus 0.5% prednisolone versus 0.9% saline in acute endogenous nongranulomatous anterior uveitis. Br J Ophthalmol (1982) 1.00
Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol (2009) 0.98
Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol (2007) 0.97
Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease. Arch Ophthalmol (1986) 0.97
Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol (2003) 0.94
Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond) (2008) 0.93
Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol (2005) 0.93
Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol (2007) 0.92
Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology (1998) 0.90
The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol (2005) 0.90
Arthritis and uveitis in children. A pediatric rheumatology perspective. Am J Ophthalmol (2003) 0.89
Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol (1996) 0.89
Uveitis as a cause of visual loss in arthritides and comparable conditions. J Rheumatol (2001) 0.88
Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) (2001) 0.87
Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol (1986) 0.87
Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol (2010) 0.86
Treatment of uveitis with methotrexate. Am J Ophthalmol (1969) 0.86
Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol (2008) 0.86
Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol (2000) 0.86
Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology (2002) 0.85
Efficacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol (1985) 0.85
Topical indometacin, a prostaglandin inhibitor, in acute anterior uveitis. A controlled clinical trial of non-steroid versus steroid anti-inflammatory treatment. Acta Ophthalmol (Copenh) (1991) 0.84
Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol (2003) 0.84
Visual prognosis in children with chronic anterior uveitis and arthritis. J Rheumatol (1994) 0.83
Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol (1997) 0.83
Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int (2005) 0.82
Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res (2009) 0.81
Nonsteroidal anti-inflammatory drug therapy in chronic childhood iridocyclitis. Am J Dis Child (1988) 0.81
A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation. Ocul Immunol Inflamm (2004) 0.81
Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis (2006) 0.80
[Interdisciplinary and evidence-based treatment guideline for juvenile idiopathic arthritis]. Klin Padiatr (2008) 0.79
Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis. Eye (Lond) (2008) 0.79
Topical treatment of uveitis resulting in adrenal insufficiency. Acta Paediatr (2008) 0.79
Late onset uveitis in juvenile-type chronic polyarthritis controlled with prednisolone, cyclosporin A and methotrexate. Clin Exp Rheumatol (1998) 0.79
Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int (2003) 0.77
[Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood]. Klin Monbl Augenheilkd (2007) 0.77
Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum (2004) 0.77
Chlorambucil in the treatment of intractable Uveitis associated with juvenile chronic arthritis. J Rheumatol (1985) 0.76
Methotrexate and chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol (2006) 0.76
[Topical and systemic corticosteroid therapy for uveitis in childhood]. Klin Monbl Augenheilkd (2007) 0.75
Sulphasalazine therapy in chronic uveitis of children with chronic arthritis. Asian Pac J Allergy Immunol (1997) 0.75
[EBM analysis: classic DMARDs (disease-modifying antirheumatic drugs) and immunosuppressants in arthritis and uveitis]. Klin Monbl Augenheilkd (2007) 0.75
[Juvenile uveitis]. Klin Monbl Augenheilkd (1987) 0.75
[Long-term prophylaxis of recurring spondylitic iridocyclitis with antimalarials and non-steroidal antiphlogistics]. Z Rheumatol (1982) 0.75
Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al. Arthritis Rheum (2008) 0.75
[Cyclosporin A in therapy of chronic uveitis in childhood]. Ophthalmologe (1996) 0.75
[Juvenile idiopathic arthritis and uveitis: epidemiology including data from a national database]. Klin Monbl Augenheilkd (2007) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Active immunotherapy for acute lymphoblastic leukaemia. Lancet (1969) 13.03
Generation and analysis of 280,000 human expressed sequence tags. Genome Res (1996) 8.27
Language bias in randomised controlled trials published in English and German. Lancet (1997) 7.29
Gene Ontology annotations and resources. Nucleic Acids Res (2012) 6.13
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Spurious precision? Meta-analysis of observational studies. BMJ (1998) 5.45
Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet (2000) 4.83
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (1996) 4.26
Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med (1998) 4.13
A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology (1999) 4.10
Cancer in the elderly: why so badly treated? Lancet (1990) 3.67
European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol (2009) 3.56
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Picosecond kinetics of the initial photochemical electron-transfer reaction in bacterial photosynthetic reaction centers. Biochemistry (1985) 3.30
Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut (2009) 3.24
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 2.94
Large-scale reductions in speeding and accidents in Canada and Israel: a behavioral ecological perspective. J Appl Behav Anal (1985) 2.93
Peroxisomal protein import is conserved between yeast, plants, insects and mammals. EMBO J (1990) 2.93
Advertisements for donepezil (Aricept) in the BMJ. Local committee has declined to approve NHS hospital prescription of donepezil. BMJ (1997) 2.89
Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J (1996) 2.80
The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest (2001) 2.77
Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol (2001) 2.77
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72
Non-culture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol Infect (1997) 2.67
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med (1999) 2.67
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. J Exp Med (1999) 2.62
Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.52
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
NZB mouse system for production of monoclonal antibodies to weak bacterial antigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia coli K1 and group B meningococci. Proc Natl Acad Sci U S A (1985) 2.49
Retinal capillary blood flow measurement with a scanning laser ophthalmoscope. Preliminary results. Ophthalmology (1991) 2.44
Retinal microcirculation in patients with diabetes mellitus: dynamic and morphological analysis of perifoveal capillary network. Br J Ophthalmol (1991) 2.30
Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol (1996) 2.30
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood (2000) 2.21
Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol (2003) 2.20
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) (2005) 2.19
Tumor seeding following laparoscopy: international survey. World J Surg (1999) 2.18
The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis (2004) 2.16
Sequence and analysis of chromosome 5 of the plant Arabidopsis thaliana. Nature (2000) 2.16
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
The International Classification of Functioning, Disability and Health: a new tool for understanding disability and health. Disabil Rehabil (2003) 2.14
Drosophila Stardust is a partner of Crumbs in the control of epithelial cell polarity. Nature (2001) 2.12
Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftment after autologous blood cell transplantation. Br J Haematol (1998) 2.10
Low infection rate and long durability of nontunneled silastic catheters. A safe and cost-effective alternative for long-term venous access. Arch Intern Med (1993) 2.10
Immunology of the eye and the joint. Immunol Today (1994) 2.10
High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus (1998) 2.07
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol (1993) 2.07
[Benign symmetric lipomatosis--Launois-Besaude syndrome. A case report]. Tidsskr Nor Laegeforen (1996) 2.05
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
Non-O157:H7 pathogenic Shiga toxin-producing Escherichia coli: phenotypic and genetic profiling of virulence traits and evidence for clonality. J Infect Dis (1999) 2.04
Potential use of copper surfaces to reduce survival of epidemic meticillin-resistant Staphylococcus aureus in the healthcare environment. J Hosp Infect (2006) 2.04
Intuitive hypertext-based molecular identification of micro-organisms. Lancet (1999) 2.01
Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis (2006) 1.98
The large plasmids of Shiga-toxin-producing Escherichia coli (STEC) are highly variable genetic elements. Microbiology (1999) 1.97
Independent effects of IgG and complement upon human polymorphonuclear leukocyte function. J Immunol (1976) 1.97
Three genes coding for subunits of the membrane sector (F0) of the Escherichia coli adenosine triphosphatase complex. J Bacteriol (1981) 1.97
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia (2009) 1.93
Use of repetitive sequences and the polymerase chain reaction technique to classify genetically related Bradyrhizobium japonicum serocluster 123 strains. Appl Environ Microbiol (1993) 1.92
Detection of Mycoplasma pneumoniae by polymerase chain reaction and nonradioactive hybridization in microtiter plates. J Clin Microbiol (1993) 1.91
STUDIES IN THE PHYSIOLOGY OF ARTIFICIAL FEVER. I. CHANGES IN THE BLOOD VOLUME AND WATER BALANCE. J Clin Invest (1938) 1.91
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
The survival of Escherichia coli O157 on a range of metal surfaces. Int J Food Microbiol (2005) 1.89
A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate Eps15 and conserved in evolution. Proc Natl Acad Sci U S A (1995) 1.87
Collaborative annotation of genes and proteins between UniProtKB/Swiss-Prot and dictyBase. Database (Oxford) (2009) 1.85
Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res (1988) 1.84
Structural and transcription analysis of two homologous genes for the P700 chlorophyll a-apoproteins in Chlamydomonas reinhardii: evidence for in vivo trans-splicing. EMBO J (1987) 1.84
Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J Biol Chem (1991) 1.83
Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol Microbiol (1994) 1.82
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Mutation in the SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. JAMA (2001) 1.81
Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med (2008) 1.81
[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81
Src phosphorylation of the epidermal growth factor receptor at novel sites mediates receptor interaction with Src and P85 alpha. J Biol Chem (1995) 1.81
Necessity of molecular techniques to distinguish between Neisseria meningitidis strains isolated from patients with meningococcal disease and from their healthy contacts. J Clin Microbiol (1998) 1.80
Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal pain, diarrhea and other signs and symptoms (CEDAP-Plus Study). Endoscopy (2007) 1.79
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis (2008) 1.78
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
Isolation and characterization of a kanamycin resistance plasmid from Staphylococcus aureus. Antimicrob Agents Chemother (1974) 1.77
Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine (1998) 1.74
Crystal structure of the xanthine oxidase-related aldehyde oxido-reductase from D. gigas. Science (1995) 1.74
Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N Engl J Med (1996) 1.73
Mechanisms of neisserial serum resistance. Mol Microbiol (1999) 1.71
A general method for the specific isolation of peptides containing modified residues, using insoluble antibody columns. Biochemistry (1971) 1.70
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology (2011) 1.69
Social marketing-based communications to integrate and support the HEALTHY study intervention. Int J Obes (Lond) (2009) 1.69
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Transscleral diode laser cyclophotocoagulation for the treatment of refractory glaucoma secondary to inflammatory eye diseases. Br J Ophthalmol (2000) 1.68
Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules. Mol Gen Genet (1997) 1.68
The changing pattern of mortality and morbidity from radical cystectomy. BJU Int (2000) 1.68
Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck (1991) 1.66
Diagnostics of neisseriaceae and moraxellaceae by ribosomal DNA sequencing: ribosomal differentiation of medical microorganisms. J Clin Microbiol (2001) 1.66